AI assistant
Vera Therapeutics, Inc. — Director's Dealing 2025
Feb 20, 2025
31944_dirs_2025-02-20_2181e48f-71ca-4b1b-91a3-603350f8bb9f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2025-02-18
Reporting Person: Brenner Robert (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-18 | Class A Common Stock | A | 26900 | — | Acquired | 27474 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-18 | Stock Option (right to buy) | $29.18 | A | 53800 | Acquired | 2035-02-17 | Class A Common Stock (53800) | Direct |
Footnotes
F1: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
F2: Includes 574 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 13, 2024.
F3: 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.